Gilead Remdesivir Production: Partnering, Licensing Concerns And Beximco’s Plans
Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19. Healthcare activists say past licensing models used by the US firm are flawed and unacceptable during a global health emergency.
You may also be interested in...
Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials
The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.
Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.